In insulin-naïve individuals with type 2 diabetes (ONWARDS 1, 3, and 5), once-weekly icodec demonstrated superior HbA1c reductions compared to degludec (treatment difference -0.2% at week 26, 95% CI -0.3 to -0.1), glargine (treatment difference -0.19% at week 52, 95% CI -0.36 to -0.03), and to once-daily basal insulin analogues (treatment difference -0.38% at week 52, 95% CI -0.66 to -0.09) (10–12). This evidence concerns the gene INS and type 2 diabetes mellitus.